Barclays
SAGE

Barclays’s Sage Therapeutics SAGE Stock Holding History

Barclays’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-60,000
Closed -$652K – 5449
2024
Q2 		$652K Buy
60,000
+30,000
+100% +$384K ﹤0.01% 2875
2024
Q1 		$562K Buy
30,000
+3,000
+11% +$69.2K ﹤0.01% 3516
2023
Q4 		$585K Buy
+27,000
New +$535K ﹤0.01% 3782
2020
Q2 		– Sell
-100
Closed -$3K – 6151
2020
Q1 		$3K Sell
100
-4,200
-98% -$243K ﹤0.01% 5993
2019
Q4 		$310K Buy
4,300
+3,000
+231% +$369K ﹤0.01% 4701
2019
Q3 		$182K Sell
1,300
-200
-13% -$33.5K ﹤0.01% 5041
2019
Q2 		$275K Buy
1,500
+200
+15% +$34.1K ﹤0.01% 4825
2019
Q1 		$207K Sell
1,300
-89,700
-99% -$13M ﹤0.01% 4805
2018
Q4 		$8.72M Buy
91,000
+88,000
+2,933% +$10.1M 0.01% 1229
2018
Q3 		$424K Buy
3,000
+600
+25% +$92.6K ﹤0.01% 4410
2018
Q2 		$376K Sell
2,400
-200
-8% -$31.4K ﹤0.01% 4197
2018
Q1 		$419K Sell
2,600
-348,300
-99% -$59.1M ﹤0.01% 4146
2017
Q4 		$57.8M Buy
350,900
+347,800
+11,219% +$33.7M 0.05% 346
2017
Q3 		$193K Sell
3,100
-426,900
-99% -$33.5M ﹤0.01% 4454
2017
Q2 		$34.2M Buy
430,000
+429,800
+214,900% +$31.1M 0.04% 395
2017
Q1 		$14K Buy
+200
New +$11.7K ﹤0.01% 5962
2016
Q4 		– Sell
-90,000
Closed -$4.14M – 6804
2016
Q3 		$4.14M Sell
90,000
-141,000
-61% -$5.74M ﹤0.01% 1434
2016
Q2 		$6.96M Buy
+231,000
New +$7.7M 0.01% 1078

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Barclays's SAGE Position: Q3 2025 in Review

Barclays sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 99,618 shares — an estimated $909K sold.

Barclays first reported a position in SAGE in Q4 2014 and held it in 43 quarters. The position peaked at $33.7M in Q4 2017. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Barclays reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Barclays sold 99,618 Sage Therapeutics shares in Q3 2025, an estimated $909K.
  • Barclays first reported a position in Sage Therapeutics in Q4 2014 and held it in 43 quarters.
  • Barclays's Sage Therapeutics position peaked at $33.7M in Q4 2017.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Barclays's 13F filing for Q3 2025, filed 12 Nov 2025.